Biology and Genetics: Understanding Your Specific Subtype

The biology of thyroid cancer is rooted in the follicular cells—the cells in your thyroid responsible for making thyroid hormone. When these cells undergo specific genetic changes, they can develop into different types of “differentiated” thyroid cancer. Understanding the subtype and genetic mutations of your tumor helps your care team predict how it might behave and determine the most effective treatment plan.

Two Paths: Papillary vs. Follicular

While both start in the same cell type, Papillary Thyroid Carcinoma (PTC) and Follicular Thyroid Carcinoma (FTC) differ in how they typically spread:

• Papillary (PTC): This is the most common form. It frequently spreads via the lymphatic system to the lymph nodes in the neck.
• Follicular (FTC): This type is more likely to spread through the bloodstream (hematogenous spread). Because of this, when it does spread, it is more commonly found in distant sites like the lungs or bones.

The NIFTP Reclassification: A Major Change

In 2016, the medical community made a significant change to how a specific thyroid growth is named. What was once called “encapsulated follicular variant of papillary thyroid carcinoma” is now called NIFTP (Non-invasive follicular thyroid neoplasm with papillary-like nuclear features) ^[1][2].

This change happened because doctors realized this specific growth is non-invasive and behaves in an indolent (non-aggressive) way ^[3]. By removing the word “cancer” from its name, thousands of patients are now spared from overdiagnosis and overtreatment ^[2].

Important Diagnostic Sequencing: It is crucial to understand that NIFTP cannot be definitively diagnosed from a Fine Needle Aspiration (FNA) biopsy alone. Because the pathologist must examine the entire capsule around the tumor to prove it is “non-invasive” (no cancer cells breaking through the border), an initial surgery (usually a lobectomy) is still required to get the diagnosis ^[1][4]. However, once diagnosed with NIFTP, this simple lobectomy is considered a complete cure, and you are spared from total thyroidectomy and Radioactive Iodine.

Genetic “Drivers” of Thyroid Cancer

Your doctor may test your tumor for specific mutations that act as the “engine” driving the cancer’s growth ^[5].

• BRAF (specifically BRAF V600E): Found in a majority of Papillary cancers, this mutation is often associated with spread to the neck lymph nodes ^[6]. While it sounds scary, most people with a BRAF mutation still have an excellent prognosis.
• RAS: These mutations are more common in Follicular-pattern tumors and are often present in NIFTP ^[7].
• TERT Promoter: This is a rarer mutation that can act as a marker for a more aggressive tumor ^[8].

The “High-Risk” Duo: The most important genetic finding is the combination of a BRAF (or RAS) mutation and a TERT mutation occurring together. This “duo” can make a tumor more aggressive and less responsive to traditional treatments like radioactive iodine ^[9]. Knowing if these mutations are present allows your doctor to personalize your follow-up and treatment intensity.